TrialGut and liver2023

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.

Jihye Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.